Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma

Li,Qian; Yuan,Jianjun; Wang,Yan; Zhai,Yuanpeng

doi:10.3892/ol.2017.6276

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma

Authors:
- Qian Li
- Jianjun Yuan
- Yan Wang
- Yuanpeng Zhai
View Affiliations

Affiliations: Department of Medical Ultrasonics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Medical Ultrasonics, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China
Published online on: May 29, 2017 https://doi.org/10.3892/ol.2017.6276
Pages: 1439-1444
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association between the BRAF V600E mutation and ultrasound features of the thyroid in papillary thyroid carcinoma (PTC). Fresh thyroid carcinoma tissue and paracarcinoma tissue were obtained from 34 patients undergoing surgery for PTC. The BRAF V600E mutation was detected by PCR amplification and direct DNA sequencing. The thyroid ultrasound results were compared between patients with and without the BRAF V600E mutation. Eighteen out of 34 cases were identified with the BRAF V600E mutation (52.9%), while 16 cases did not have the BRAF V600E mutation (47.1%). Additionally, no BRAF V600E mutation was detected in paracarcinoma tissue in the 34 cases. The results of ultrasound imaging suggested that there were no significant differences in tumor size, whether the border was clear, or in tumor calcification (presence or absence) between patients with and without BRAF V600E mutation (P>0.05). The BRAF V600E mutation rate was high in patients with PTC. There was no significant correlation between BRAF V600E mutation and thyroid ultrasound features. Thyroid ultrasound features are therefore unable to predict the presence of the BRAF V600E mutation in patients with PTC.

View Figures

View References

1	Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
2	Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K and Takenoshita S: BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 22:6455–6457. 2003. View Article : Google Scholar : PubMed/NCBI
3	Xu X, Quiros RM, Gattuso P, Ain KB and Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63:4561–4567. 2003.PubMed/NCBI
4	Ikawa S, Fukui M, Ueyama Y, Tamaoki N, Yamamoto T and Toyoshima K: B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol. 8:2651–2654. 1988. View Article : Google Scholar : PubMed/NCBI
5	Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
6	Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
7	Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L and Beck-Peccoz P: BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf). 61:239–243. 2004. View Article : Google Scholar : PubMed/NCBI
8	Kim KH, Kang DW, Kim SH, Seong IO and Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 45:818–821. 2004. View Article : Google Scholar : PubMed/NCBI
9	Sithanandam G, Druck T, Cannizzaro LA, Leuzzi G, Huebner K and Rapp UR: B-raf and a B-raf pseudogene are located on 7q in man. Oncogene. 7:795–799. 1992.PubMed/NCBI
10	Mercer KE and Pritchard CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. 1653:25–40. 2003.PubMed/NCBI
11	Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R and Sobrinho-Simões M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 22:4578–4580. 2003. View Article : Google Scholar : PubMed/NCBI
12	Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, et al: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 209:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
13	Lima J, Trovisco V, Soares P, Máximo V, Magalhães J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, et al: Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 230:149–150. 2005. View Article : Google Scholar : PubMed/NCBI
14	Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W and Xing M: Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 94:1612–1617. 2009. View Article : Google Scholar : PubMed/NCBI
15	Watanabe R, Hayashi Y, Sassa M, Kikumori T, Imai T, Kiuchi T and Murata Y: Possible involvement of BRAF V600E in altered gene expression in papillary thyroid cancer. Endocr J. 56:407–414. 2009. View Article : Google Scholar : PubMed/NCBI
16	Lee JH, Lee ES and Kim YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: A meta-analysis. Cancer. 110:38–46. 2007. View Article : Google Scholar : PubMed/NCBI
17	Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, et al: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 88:5399–5404. 2003. View Article : Google Scholar : PubMed/NCBI
18	Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D and Hoon DS: Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg. 244:799–804. 2006. View Article : Google Scholar : PubMed/NCBI
19	Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J and García-Rostán G: BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf). 68:618–634. 2008. View Article : Google Scholar : PubMed/NCBI
20	Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et al: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379. 2005. View Article : Google Scholar : PubMed/NCBI
21	Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A and Basolo F: BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab. 93:3943–3949. 2008. View Article : Google Scholar : PubMed/NCBI
22	Kim DL, Song KH and Kim SK: High prevalence of carcinoma in ultrasonography-guided fine needle aspiration cytology of thyroid nodules. Endocr J. 55:135–142. 2008. View Article : Google Scholar : PubMed/NCBI
23	Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D and Ladenson PW: Detection of BRAF mutation on fine needle aspiration biopsy specimens: A new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 89:2867–2872. 2004. View Article : Google Scholar : PubMed/NCBI
24	Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park DJ, Lee HS, Cho BY, Lee ES, et al: Detection of BRAF V600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf). 65:660–666. 2006. View Article : Google Scholar : PubMed/NCBI
25	Kumagai A, Namba H, Akanov Z, Saenko VA, Meirmanov S, Ohtsuru A, Yano H, Maeda S, Anami M, Hayashi T, et al: Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J. 54:399–405. 2007. View Article : Google Scholar : PubMed/NCBI
26	Hwang J, Shin JH, Han BK, Ko EY, Kang SS, Kim JW and Chung JH: Papillary thyroid carcinoma with BRAF V600E mutation: Sonographic prediction. AJR Am J Roentgenol. 194:W425–W430. 2010. View Article : Google Scholar : PubMed/NCBI